Hot Rising Companies To Own In Right Now

Hot Rising Companies To Own In Right Now: Chelsea Therapeutics International Ltd.(CHTP)

Chelsea Therapeutics International, Ltd., a development-stage pharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutic products for the treatment of various human diseases. It is involved in developing Droxidopa, a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with primary autonomic failure and falls related to NOH in Parkinson?s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, adult attention deficit hyperactivity disorder, chronic fatigue syndrome, and freezing of gait in PD and down syndrome. The company intends to market its Droxidopa drug under the Northera brand name. It also engages in developing a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn?s disease, ankylosing spondylitis, uveitis, psoriatic ar thritis, inflammatory bowel disease, cancer, and other immunological disorders. The company?s molecule products include a portfolio of metabolically inert antifolate molecules consisting of CH-1504 and CH-4051, which are orally available molecules with anti-inflammatory, autoimmune, and anti-tumor properties that inhibit various key enzymes required for cell proliferation; and a portfolio of dihydroorotate dehydrogenase, known as the I-3D portfolio, for applications in autoimmune diseases and transplantation. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina.

Advisors' Opinion:

• [By Lauren Pollock]

  Chelsea Therapeutics International Ltd.(CHTP) said an offering of 6.67 million shares priced at $3 each, a 9.9% discount to Tuesday’s close. The development-stage pharmaceutical company said it intends to use the proceeds to fund its droxidop! a program, including regulatory and possible initial commercialization activity for its lead investigational drug candidate Northera, and for general corporate purposes. Shares dropped.

• [By Roberto Pedone]

  Chelsea Therapeutics (CHTP)
  is a specialty pharmaceutical company focused on acquisition, development and commercialization of pharmaceutical products for the treatment of a variety of human diseases. This stock closed up 9% to $2.89 in Thursday's trading session.

  Thursday's Range: $2.55-$2.98
  
  52-Week Range: $0.73-$3.25
  
  Thursday's Volume: 1.74 million
  
  Three-Month Average Volume: 1.14 million

  From a technical perspective, CHTP ripped sharply higher here right off its 50-day moving average of $2.55 with above-average volume. This stock has been uptrending strong for the last two months, with shares moving higher from its low of $1.78 t its recent high of $3.25. During that move, shares of CHTP have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CHTP within range of triggering a major breakout trade. That trade will hit if CHTP manages to take out some near-term overhead resistance levels at $3 to its 52-week high at $3.25 with high volume.

  Traders should now look for long-biased trades in CHTP as long as it's trending above its 50-day at $2.55 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.14 million shares. If that breakout triggers soon, then CHTP will set up to enter new 52-week-high territory above $3.25, which is bullish technical price action. Some possible upside targets off that breakout are its next major overhead resistance levels at $4.21 to $4.40.

• [By John Udovich]

  The biotech roller-coaster continues for investors into 2014 with small cap Chelsea Therapeutics International Ltd (NASDAQ: CHTP) set to more than double when the market opens today, ! meaning i! ts time to take a closer look at what in the world is going on with the stocks plus take a closer look at the performance of biotech peers like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/hot-rising-companies-to-own-in-right-now-2.html